Table 2.
Effect of PCSK9-inhibitor on plasma lipids, glucose, fibrinolysis, and coagulation in patients with isolated hypercholesterolemia.
| Variable | Control Group (Λ%) | Study Group (Λ%) | |
|---|---|---|---|
| Total cholesterol, mg/dL | Baseline After 90 days |
160.2 ± 10.6 157.1 ± 10.2 (−2) |
249.7 ± 12.9 152.4 ± 10.2 (−39) ***,### |
| LDL cholesterol, mg/dL | Baseline After 90 days |
96.4 ± 8.7 95.3 ± 8.1 (−1) |
181.0 ± 10.6 108.3 ± 8.4 (−40) ***,### |
| HDL cholesterol, mg/dL | Baseline After 90 days |
48.1 ± 4.3 49.1 ± 4.2 (2) |
46.2 ± 4.2 48.2 ± 4.3 (4) |
| Triglycerides, mg/dL | Baseline After 90 days |
119.2 ± 9.6 119.8 ± 10.2 (1) |
121.6 ± 11.2 109.2 ± 9.4 (−10) |
| Fasting glucose, mg/dL | Baseline After 90 days |
91 ± 4 92 ± 5 (1) |
92 ± 5 90 ± 4 (−2) |
| Prothrombin time, s | Baseline After 90 days |
13.4 ± 1.3 13.8 ± 1.4 (3) |
14.2 ± 1.2 16.4 ± 0.7 (15) |
| Partial thromboplastin time, s | Baseline After 90 days |
31.1 ± 1.4 31.8 ± 1.6 (2) |
32.1 ± 1.7 36.6 ± 1.4 (14) |
| Fibrinogen, g/L | Baseline After 90 days |
3.2 ± 0.2 3.5 ± 0.3 (9) |
3.6 ± 0.5 2.9 ± 0.4 (−20) **,# |
| Factor VII activity, % | Baseline After 90 days |
141.3 ± 15.2 142.2 ± 15.3 (1) |
143.8 ± 16.7 114.5 ± 14.1 (−20) **,## |
| Von Willebrand factor, IU/dL | Baseline After 90 days |
116.1 ± 17.2 120.2 ± 13.2 (4) |
118.1 ± 16.0 96.8 ± 11.4 (−18) # |
| PAI-1 antigen, ng/mL | Baseline After 90 days |
72.3 ± 15.2 74.4 ± 12.8 (3) |
74.9 ± 13.9 52.8 ± 9.1 (−30) ***,### |
Values are mean ± SD unless indicated otherwise. ** p < 0.01, *** p < 0.001 versus baseline; # p < 0.05, ## p < 0.01, ### p < 0.001 versus control.